Report cover image

Global Ophthalmic Corticosteroid Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 192 Pages
SKU # APRC20283236

Description

Summary

According to APO Research, The global Ophthalmic Corticosteroid market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Ophthalmic Corticosteroid is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Ophthalmic Corticosteroid is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Ophthalmic Corticosteroid is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Ophthalmic Corticosteroid is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Ophthalmic Corticosteroid include Novartis AG, Pfizer, GlaxoSmithKline, Bayer AG, Sun Pharmaceutical, Regeneron Pharmaceuticals, Orchidia, Innovative Pharmaceuticals and General Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes


This report presents an overview of global market for Ophthalmic Corticosteroid, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Ophthalmic Corticosteroid, also provides the revenue of main regions and countries. Of the upcoming market potential for Ophthalmic Corticosteroid, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ophthalmic Corticosteroid revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Ophthalmic Corticosteroid market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Ophthalmic Corticosteroid revenue, projected growth trends, production technology, application and end-user industry.

Ophthalmic Corticosteroid Segment by Company

Novartis AG
Pfizer
GlaxoSmithKline
Bayer AG
Sun Pharmaceutical
Regeneron Pharmaceuticals
Orchidia
Innovative Pharmaceuticals
General Pharmaceuticals
Genentech
Bausch Health
Bausch and Lomb
Allergan
Alimera Sciences
Ajanta Pharma
Ophthalmic Corticosteroid Segment by Type

Dexamethasone
Difluprednate
Fluorometholone
Loteprednol
Others
Ophthalmic Corticosteroid Segment by Application

Hospital Pharmacies
Research Institute
Online Pharmacies
Retail Pharmacies
Others
Ophthalmic Corticosteroid Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ophthalmic Corticosteroid market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ophthalmic Corticosteroid and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ophthalmic Corticosteroid.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Ophthalmic Corticosteroid in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Ophthalmic Corticosteroid company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ophthalmic Corticosteroid revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Ophthalmic Corticosteroid Market by Type
1.2.1 Global Ophthalmic Corticosteroid Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Dexamethasone
1.2.3 Difluprednate
1.2.4 Fluorometholone
1.2.5 Loteprednol
1.2.6 Others
1.3 Ophthalmic Corticosteroid Market by Application
1.3.1 Global Ophthalmic Corticosteroid Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Research Institute
1.3.4 Online Pharmacies
1.3.5 Retail Pharmacies
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Ophthalmic Corticosteroid Market Dynamics
2.1 Ophthalmic Corticosteroid Industry Trends
2.2 Ophthalmic Corticosteroid Industry Drivers
2.3 Ophthalmic Corticosteroid Industry Opportunities and Challenges
2.4 Ophthalmic Corticosteroid Industry Restraints
3 Global Growth Perspective
3.1 Global Ophthalmic Corticosteroid Market Perspective (2020-2031)
3.2 Global Ophthalmic Corticosteroid Growth Trends by Region
3.2.1 Global Ophthalmic Corticosteroid Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Ophthalmic Corticosteroid Market Size by Region (2020-2025)
3.2.3 Global Ophthalmic Corticosteroid Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Ophthalmic Corticosteroid Revenue by Players
4.1.1 Global Ophthalmic Corticosteroid Revenue by Players (2020-2025)
4.1.2 Global Ophthalmic Corticosteroid Revenue Market Share by Players (2020-2025)
4.1.3 Global Ophthalmic Corticosteroid Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Ophthalmic Corticosteroid Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Ophthalmic Corticosteroid Key Players Headquarters & Area Served
4.4 Global Ophthalmic Corticosteroid Players, Product Type & Application
4.5 Global Ophthalmic Corticosteroid Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Ophthalmic Corticosteroid Market CR5 and HHI
4.6.3 2024 Ophthalmic Corticosteroid Tier 1, Tier 2, and Tier 3
5 Ophthalmic Corticosteroid Market Size by Type
5.1 Global Ophthalmic Corticosteroid Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Ophthalmic Corticosteroid Revenue by Type (2020-2031)
5.3 Global Ophthalmic Corticosteroid Revenue Market Share by Type (2020-2031)
6 Ophthalmic Corticosteroid Market Size by Application
6.1 Global Ophthalmic Corticosteroid Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Ophthalmic Corticosteroid Revenue by Application (2020-2031)
6.3 Global Ophthalmic Corticosteroid Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Novartis AG
7.1.1 Novartis AG Comapny Information
7.1.2 Novartis AG Business Overview
7.1.3 Novartis AG Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.1.4 Novartis AG Ophthalmic Corticosteroid Product Portfolio
7.1.5 Novartis AG Recent Developments
7.2 Pfizer
7.2.1 Pfizer Comapny Information
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.2.4 Pfizer Ophthalmic Corticosteroid Product Portfolio
7.2.5 Pfizer Recent Developments
7.3 GlaxoSmithKline
7.3.1 GlaxoSmithKline Comapny Information
7.3.2 GlaxoSmithKline Business Overview
7.3.3 GlaxoSmithKline Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.3.4 GlaxoSmithKline Ophthalmic Corticosteroid Product Portfolio
7.3.5 GlaxoSmithKline Recent Developments
7.4 Bayer AG
7.4.1 Bayer AG Comapny Information
7.4.2 Bayer AG Business Overview
7.4.3 Bayer AG Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.4.4 Bayer AG Ophthalmic Corticosteroid Product Portfolio
7.4.5 Bayer AG Recent Developments
7.5 Sun Pharmaceutical
7.5.1 Sun Pharmaceutical Comapny Information
7.5.2 Sun Pharmaceutical Business Overview
7.5.3 Sun Pharmaceutical Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.5.4 Sun Pharmaceutical Ophthalmic Corticosteroid Product Portfolio
7.5.5 Sun Pharmaceutical Recent Developments
7.6 Regeneron Pharmaceuticals
7.6.1 Regeneron Pharmaceuticals Comapny Information
7.6.2 Regeneron Pharmaceuticals Business Overview
7.6.3 Regeneron Pharmaceuticals Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.6.4 Regeneron Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio
7.6.5 Regeneron Pharmaceuticals Recent Developments
7.7 Orchidia
7.7.1 Orchidia Comapny Information
7.7.2 Orchidia Business Overview
7.7.3 Orchidia Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.7.4 Orchidia Ophthalmic Corticosteroid Product Portfolio
7.7.5 Orchidia Recent Developments
7.8 Innovative Pharmaceuticals
7.8.1 Innovative Pharmaceuticals Comapny Information
7.8.2 Innovative Pharmaceuticals Business Overview
7.8.3 Innovative Pharmaceuticals Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.8.4 Innovative Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio
7.8.5 Innovative Pharmaceuticals Recent Developments
7.9 General Pharmaceuticals
7.9.1 General Pharmaceuticals Comapny Information
7.9.2 General Pharmaceuticals Business Overview
7.9.3 General Pharmaceuticals Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.9.4 General Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio
7.9.5 General Pharmaceuticals Recent Developments
7.10 Genentech
7.10.1 Genentech Comapny Information
7.10.2 Genentech Business Overview
7.10.3 Genentech Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.10.4 Genentech Ophthalmic Corticosteroid Product Portfolio
7.10.5 Genentech Recent Developments
7.11 Bausch Health
7.11.1 Bausch Health Comapny Information
7.11.2 Bausch Health Business Overview
7.11.3 Bausch Health Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.11.4 Bausch Health Ophthalmic Corticosteroid Product Portfolio
7.11.5 Bausch Health Recent Developments
7.12 Bausch and Lomb
7.12.1 Bausch and Lomb Comapny Information
7.12.2 Bausch and Lomb Business Overview
7.12.3 Bausch and Lomb Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.12.4 Bausch and Lomb Ophthalmic Corticosteroid Product Portfolio
7.12.5 Bausch and Lomb Recent Developments
7.13 Allergan
7.13.1 Allergan Comapny Information
7.13.2 Allergan Business Overview
7.13.3 Allergan Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.13.4 Allergan Ophthalmic Corticosteroid Product Portfolio
7.13.5 Allergan Recent Developments
7.14 Alimera Sciences
7.14.1 Alimera Sciences Comapny Information
7.14.2 Alimera Sciences Business Overview
7.14.3 Alimera Sciences Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.14.4 Alimera Sciences Ophthalmic Corticosteroid Product Portfolio
7.14.5 Alimera Sciences Recent Developments
7.15 Ajanta Pharma
7.15.1 Ajanta Pharma Comapny Information
7.15.2 Ajanta Pharma Business Overview
7.15.3 Ajanta Pharma Ophthalmic Corticosteroid Revenue and Gross Margin (2020-2025)
7.15.4 Ajanta Pharma Ophthalmic Corticosteroid Product Portfolio
7.15.5 Ajanta Pharma Recent Developments
8 North America
8.1 North America Ophthalmic Corticosteroid Revenue (2020-2031)
8.2 North America Ophthalmic Corticosteroid Revenue by Type (2020-2031)
8.2.1 North America Ophthalmic Corticosteroid Revenue by Type (2020-2025)
8.2.2 North America Ophthalmic Corticosteroid Revenue by Type (2026-2031)
8.3 North America Ophthalmic Corticosteroid Revenue Share by Type (2020-2031)
8.4 North America Ophthalmic Corticosteroid Revenue by Application (2020-2031)
8.4.1 North America Ophthalmic Corticosteroid Revenue by Application (2020-2025)
8.4.2 North America Ophthalmic Corticosteroid Revenue by Application (2026-2031)
8.5 North America Ophthalmic Corticosteroid Revenue Share by Application (2020-2031)
8.6 North America Ophthalmic Corticosteroid Revenue by Country
8.6.1 North America Ophthalmic Corticosteroid Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Ophthalmic Corticosteroid Revenue by Country (2020-2025)
8.6.3 North America Ophthalmic Corticosteroid Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Ophthalmic Corticosteroid Revenue (2020-2031)
9.2 Europe Ophthalmic Corticosteroid Revenue by Type (2020-2031)
9.2.1 Europe Ophthalmic Corticosteroid Revenue by Type (2020-2025)
9.2.2 Europe Ophthalmic Corticosteroid Revenue by Type (2026-2031)
9.3 Europe Ophthalmic Corticosteroid Revenue Share by Type (2020-2031)
9.4 Europe Ophthalmic Corticosteroid Revenue by Application (2020-2031)
9.4.1 Europe Ophthalmic Corticosteroid Revenue by Application (2020-2025)
9.4.2 Europe Ophthalmic Corticosteroid Revenue by Application (2026-2031)
9.5 Europe Ophthalmic Corticosteroid Revenue Share by Application (2020-2031)
9.6 Europe Ophthalmic Corticosteroid Revenue by Country
9.6.1 Europe Ophthalmic Corticosteroid Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Ophthalmic Corticosteroid Revenue by Country (2020-2025)
9.6.3 Europe Ophthalmic Corticosteroid Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Ophthalmic Corticosteroid Revenue (2020-2031)
10.2 China Ophthalmic Corticosteroid Revenue by Type (2020-2031)
10.2.1 China Ophthalmic Corticosteroid Revenue by Type (2020-2025)
10.2.2 China Ophthalmic Corticosteroid Revenue by Type (2026-2031)
10.3 China Ophthalmic Corticosteroid Revenue Share by Type (2020-2031)
10.4 China Ophthalmic Corticosteroid Revenue by Application (2020-2031)
10.4.1 China Ophthalmic Corticosteroid Revenue by Application (2020-2025)
10.4.2 China Ophthalmic Corticosteroid Revenue by Application (2026-2031)
10.5 China Ophthalmic Corticosteroid Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Ophthalmic Corticosteroid Revenue (2020-2031)
11.2 Asia Ophthalmic Corticosteroid Revenue by Type (2020-2031)
11.2.1 Asia Ophthalmic Corticosteroid Revenue by Type (2020-2025)
11.2.2 Asia Ophthalmic Corticosteroid Revenue by Type (2026-2031)
11.3 Asia Ophthalmic Corticosteroid Revenue Share by Type (2020-2031)
11.4 Asia Ophthalmic Corticosteroid Revenue by Application (2020-2031)
11.4.1 Asia Ophthalmic Corticosteroid Revenue by Application (2020-2025)
11.4.2 Asia Ophthalmic Corticosteroid Revenue by Application (2026-2031)
11.5 Asia Ophthalmic Corticosteroid Revenue Share by Application (2020-2031)
11.6 Asia Ophthalmic Corticosteroid Revenue by Country
11.6.1 Asia Ophthalmic Corticosteroid Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Ophthalmic Corticosteroid Revenue by Country (2020-2025)
11.6.3 Asia Ophthalmic Corticosteroid Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Ophthalmic Corticosteroid Revenue (2020-2031)
12.2 SAMEA Ophthalmic Corticosteroid Revenue by Type (2020-2031)
12.2.1 SAMEA Ophthalmic Corticosteroid Revenue by Type (2020-2025)
12.2.2 SAMEA Ophthalmic Corticosteroid Revenue by Type (2026-2031)
12.3 SAMEA Ophthalmic Corticosteroid Revenue Share by Type (2020-2031)
12.4 SAMEA Ophthalmic Corticosteroid Revenue by Application (2020-2031)
12.4.1 SAMEA Ophthalmic Corticosteroid Revenue by Application (2020-2025)
12.4.2 SAMEA Ophthalmic Corticosteroid Revenue by Application (2026-2031)
12.5 SAMEA Ophthalmic Corticosteroid Revenue Share by Application (2020-2031)
12.6 SAMEA Ophthalmic Corticosteroid Revenue by Country
12.6.1 SAMEA Ophthalmic Corticosteroid Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Ophthalmic Corticosteroid Revenue by Country (2020-2025)
12.6.3 SAMEA Ophthalmic Corticosteroid Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.